Novo Nordisk AS's Total Assets for the quarter that ended in Mar. 2026 was €74,819 Mil.
Warning Sign:
If a company builds assets at 32.3% a year, faster than its revenue growth rate of 23% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Novo Nordisk AS's average Total Assets Growth Rate was 20.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 33.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 32.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 22.90% per year.
During the past 13 years, Novo Nordisk AS's highest 3-Year average Total Assets Growth Rate was 35.40%. The lowest was -1.70%. And the median was 10.80%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Novo Nordisk AS's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Novo Nordisk AS Total Assets Related Terms
Novo Nordisk AS Total Assets Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Novo Nordisk AS's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS (HAM:NOVA) has a Total Assets of €74,819 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Total Assets too high?
Novo Nordisk AS's current Total Assets is €74,819 Mil. Overall, Novo Nordisk AS has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Total Assets compare to LLY and JNJ?
Novo Nordisk AS's Total Assets of €74,819 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Total Assets is €74,819 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (HAM:NOVA) is currently considered Significantly Undervalued. The stock's GF Value™ is €119.41, compared to a current price of €42.80 — trading 64.2% below its estimated fair value. The current Total Assets is €74,819 Mil. Novo Nordisk AS's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Novo Nordisk AS (HAM:NOVA), the current Total Assets is €74,819 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (HAM:NOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €42.80 is trading 64.2% below its estimated GF Value™ of €119.41.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for HAM:NOVA:
Total Assets: €74,819 Mil
GF Value™: €119.41 vs. price of €42.80 (64.2% below fair value)
No single metric tells the full story. See the HAM:NOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
84GF Score
Get the complete analysis for HAM:NOVA
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:NOVA has been successfully added to your 
